China Pharma Holdings, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. The company develops, manufactures, and markets pharmaceutical products in China; substantially all operations and revenue are in the PRC.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $1.97 million | $1.98 million | $5.18 million | $6.75 million |
| Gross profit (loss) | ($138,000) | ($296,000) | ($537,000) | $47,000 |
| Gross margin | (7.0%) | (15.0%) | (10.4%) | 0.7% |
| Operating loss | ($689,000) | ($762,000) | ($2.38 million) | ($2.21 million) |
| Net loss | ($791,000) | ($827,000) | ($2.71 million) | ($2.42 million) |
| Loss per share, basic and diluted | ($0.02) | ($0.02) | ($0.06) | ($0.05) |
- Q3 revenue was essentially unchanged year over year. Lower cost of the products sold narrowed the quarterly gross loss, while selling and R&D expenses increased.
- Nine-month revenue fell 23%; management attributed the decline chiefly to lower sales of Cefaclor Dispersible Tablets, Alginic Sodium Diester Injection, and Vitamin B6. Fixed costs did not decline with revenue, pushing the period to a gross loss.
- Nine-month interest expense rose to $338,000 from $209,000. Foreign-currency translation reduced comprehensive income by $1.17 million for the nine months, versus a $75,000 gain in 2021.
- At September 30, cash was $2.09 million, down from $4.86 million at year-end 2021. Current assets were $5.61 million and current liabilities $12.63 million; total liabilities were $13.37 million and stockholders’ equity $2.83 million.
- Nine-month operating cash flow was negative $994,000, investing cash flow negative $429,000, and financing cash flow negative $1.10 million. Cash decreased $2.77 million, including a $251,000 unfavorable exchange-rate effect.
- Reported borrowings included $3.06 million of bank lines of credit, a $4.55 million current convertible note, and $2.45 million of related-party borrowings. The company repaid bank debt during the period; line-of-credit principal of $1.20 million was due in 2022 and $1.86 million in 2023.
Changes, outlook, and material risks
- Going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements. It expects continued operating losses and cites production, debt-service, selling, and administrative costs. Management plans to improve advance-payment sales and collections, pursue strategic alternatives to accelerate nutrition products, and seek loans secured by fixed assets. The plans were not finalized or sufficiently within the company’s control to alleviate the substantial doubt.
- Convertible note and dilution: The $5.25 million original-principal note was issued for $5.00 million and bears 5% interest, compounded daily. The investor may redeem up to $500,000 per month after the specified waiting period, in cash or shares priced at 85% of the lowest VWAP in the preceding ten trading days. The filing reports 31.26 million shares issuable under the redemption formula at September 30, compared with 11.98 million at year-end. During the first nine months, $700,000 of principal was converted through redemptions into approximately 3.11 million shares. A further $100,000 redemption resulted in 892,857 shares issued in October.
- Liquidity constraints: The company’s $2.09 million cash balance was held in its Chinese subsidiary and management did not expect it to be available for parent-company or shareholder payments. PRC restrictions may limit currency conversion and remittances. The CEO advanced $1.09 million outstanding at quarter-end; future support is not assured.
- Receivables and concentration: Net trade receivables were $448,000 after a $16.43 million allowance. Management reported 97.2% of receivables were more than 720 days old. Three customers represented 52.8%, 11.4%, and 10.4% of receivables; four products generated about 77% of nine-month sales.
- Operating and market risks: China’s centralized drug procurement can sharply reduce winning-bid prices, while consistency-evaluation requirements require investment and time. The company is progressing an evaluation for one product and was awaiting NMPA on-site verification after submitting supplementary documents. COVID-19 restrictions, PRC policy and economic changes, and exchange-rate and remittance controls may affect operations.
- Controls: Management concluded disclosure controls were ineffective due to a material weakness involving insufficient personnel knowledgeable in U.S. GAAP financial reporting. Management nevertheless stated the interim financial statements were fairly stated in all material respects.
- No formal financial guidance was provided. Management described strategic priorities and risks but cautioned that forward-looking statements are uncertain. No off-balance-sheet arrangements were reported.
Key facts for investors to verify
- Whether the company can fund operations and meet debt maturities, and whether its going-concern plans become actionable.
- The note’s redemption terms, outstanding balance, potential share issuance, and resulting dilution; also the October 2022 redemption disclosed as a subsequent event.
- Recoverability and collection timing of the heavily aged receivables, the adequacy of the allowance, and customer concentration.
- Availability of PRC cash for group obligations and the effect of currency-conversion and remittance restrictions.
- Progress on NMPA product verification, consistency-evaluation costs, and the economics of products exposed to centralized procurement.
- Remediation of the disclosed material weakness in financial-reporting controls.